Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.

Pickar JH, Lavenberg J, Pan K, Komm BS.

Menopause. 2018 Mar;25(3):273-285. doi: 10.1097/GME.0000000000000992.

PMID:
29088019
2.

Efficacy and safety of bazedoxifene in postmenopausal Latino women with osteoporosis.

Bueno JAH, Arias L, Yu CR, Williams R, Komm BS.

Menopause. 2017 Sep;24(9):1033-1039. doi: 10.1097/GME.0000000000000889.

PMID:
28837504
3.

Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies.

Pinkerton JV, Bushmakin AG, Bobula J, Lavenberg J, Komm BS, Abraham L.

Menopause. 2017 Dec;24(12):1378-1385. doi: 10.1097/GME.0000000000000918.

PMID:
28654628
4.

Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA.

Pinkerton JV, Bushmakin AG, Bobula J, Lavenberg J, Komm BS, Abraham L.

Menopause. 2017 Dec;24(12):1372-1377. doi: 10.1097/GME.0000000000000935.

PMID:
28609389
5.

Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.

Pinkerton JV, Bushmakin AG, Komm BS, Abraham L.

Maturitas. 2017 Jun;100:57-63. doi: 10.1016/j.maturitas.2017.03.315. Epub 2017 Mar 22.

PMID:
28539177
6.

Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene.

Pinkerton JV, Bushmakin AG, Abraham L, Komm BS, Bobula J.

Menopause. 2017 Sep;24(9):1011-1016. doi: 10.1097/GME.0000000000000888.

PMID:
28463874
7.

Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.

Abraham L, Bushmakin AG, Dragon E, Komm BS, Pinkerton JV.

Maturitas. 2016 Dec;94:173-179. doi: 10.1016/j.maturitas.2016.09.010. Epub 2016 Sep 16.

PMID:
27823739
8.

Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women.

Kagan R, Komm BS, Ryan KA, Lavenberg J, Yu CR, Pinkerton JV.

Menopause. 2016 Nov;23(11):1204-1213.

PMID:
27433860
9.

Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.

Archer DF, Freeman EW, Komm BS, Ryan KA, Yu CR, Mirkin S, Pinkerton JV.

J Womens Health (Larchmt). 2016 Nov;25(11):1102-1111. Epub 2016 Sep 27.

PMID:
27676118
10.

CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.

Hadji P, Ryan KA, Yu CR, Mirkin S, Komm BS.

Climacteric. 2016 Oct;19(5):482-7. doi: 10.1080/13697137.2016.1216958. Epub 2016 Aug 14.

PMID:
27631562
11.

Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials.

Gallagher JC, Palacios S, Ryan KA, Yu CR, Pan K, Kendler DL, Mirkin S, Komm BS.

Menopause. 2016 Oct;23(10):1083-91. doi: 10.1097/GME.0000000000000694.

PMID:
27404034
12.

Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters.

Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Komm BS.

Menopause. 2016 Oct;23(10):1060-6. doi: 10.1097/GME.0000000000000678.

PMID:
27404028
13.

Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effects.

Pinkerton JV, Bushmakin AG, Abraham L, Cappelleri JC, Komm BS.

Menopause. 2016 Oct;23(10):1092-101. doi: 10.1097/GME.0000000000000679.

PMID:
27404026
14.

Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.

Pinkerton JV, Pickar JH, Ryan KA, Yu CR, Mirkin S, Komm BS.

Menopause. 2016 Jun;23(6):611-20. doi: 10.1097/GME.0000000000000617.

PMID:
27163519
15.

Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial.

Palacios S, Williams R, Mirkin S, Pan K, Arias L, Komm BS.

Menopause. 2016 Jul;23(7):771-7. doi: 10.1097/GME.0000000000000610.

PMID:
27116464
16.

Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene.

Kagan R, Goldstein SR, Pickar JH, Komm BS.

Ther Clin Risk Manag. 2016 Apr 7;12:549-62. doi: 10.2147/TCRM.S63833. eCollection 2016. Review.

17.

Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.

Mirkin S, Pinkerton JV, Kagan R, Thompson JR, Pan K, Pickar JH, Komm BS, Archer DF.

J Womens Health (Larchmt). 2016 May;25(5):431-42. doi: 10.1089/jwh.2015.5351. Epub 2016 Apr 8.

PMID:
27058301
18.

The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.

Black D, Messig M, Yu CR, Assaf AR, Komm BS, Mirkin S, Boucher M.

Menopause. 2016 Apr;23(4):376-82. doi: 10.1097/GME.0000000000000541.

PMID:
26694733
19.

The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.

Komm BS, Morgenstern D, A Yamamoto L, Jenkins SN.

Expert Rev Clin Pharmacol. 2015;8(6):769-84. doi: 10.1586/17512433.2015.1099432. Epub 2015 Oct 20. Review.

PMID:
26482902
20.

Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.

Pickar JH, Komm BS.

Post Reprod Health. 2015 Sep;21(3):112-21. doi: 10.1177/2053369115599090. Epub 2015 Aug 19. Review.

PMID:
26289836

Supplemental Content

Loading ...
Support Center